SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers has completed a highly successful, oversubscribed Series A funding of £2.1m.

The funding round was jointly led by Origin Capital and Meltwind, and had follow on investment from all existing investors including Abcam and o2H Ventures. The success of this funding round is testament to the progress made with collaborators in evaluating PolyNaut® for penetrating the blood-brain barrier (BBB) and the launch by Abcam of PolyNaut®-Dye products.